GPMDB00365OtherHarel M, et al.InstrumentNot AvailableNot availableHomo_sapiens_viruses, Humangeiger@post.tau.ac.il25624350Tel Aviv University, Israel, et al.http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007509http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007526http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007527http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007528http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007529http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007522http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007523http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007524http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007525http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007520http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007521http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007519http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007516http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007517http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007518http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007533http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007511http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32390007522http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007534http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007512http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007535http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007513http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007514http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007536http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007530http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007531http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007532http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007510Not availableGPMDBUnbiased proteomic analysis of plasma samples holds the promise to reveal clinically invaluable disease biomarkers. However, the tremendous dynamic range of the plasma proteome has so far hampered the identification of such low abundant markers. To overcome this challenge we analyzed the plasma microparticle proteome, and reached an unprecedented depth of over 3000 plasma proteins in single runs. To add a quantitative dimension, we developed PROMIS-Quan-PROteomics of MIcroparticles with Super-Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantification, a novel mass spectrometry-based technology for plasma microparticle proteome quantification. PROMIS-Quan enables a two-step relative and absolute SILAC quantification. First, plasma microparticle proteomes are quantified relative to a super-SILAC mix composed of cell lines from distinct origins. Next, the absolute amounts of selected proteins of interest are quantified relative to the super-SILAC mix. We applied PROMIS-Quan to prostate cancer and compared plasma microparticle samples of healthy individuals and prostate cancer patients. We identified in total 5374 plasma-microparticle proteins, and revealed a predictive signature of three proteins that were elevated in the patient-derived plasma microparticles. Finally, PROMIS-Quan enabled determination of the absolute quantitative changes in prostate specific antigen (PSA) upon treatment. We propose PROMIS-Quan as an innovative platform for biomarker discovery, validation, and quantification in both the biomedical research and in the clinical worlds.Proteomics of microparticles with SILAC Quantification (PROMIS-Quan): a novel proteomic method for plasma biomarker quantification.Harel Michal M,Oren-Giladi Pazit P,Kaidar-Person Orit O,Shaked Yuval Y,Geiger Tamar T,Harel Michal M, Oren-Giladi Pazit P, Kaidar-Person Orit O, Shaked Yuval Y, Geiger Tamar TPlasma, Fresh, Fresh Frozen Plasmas, Fresh Frozen, Blood Plasma, portion of blood plasma, Frozen Plasma, Procedures, Fresh Frozen Plasma, Blood, portion of plasma, Methodological, Procedure, Methodological Study, Plasmas, plan specification, Study, Frozen Plasmas, method, blood plasm, Methodological Studies, Method, method used in an experiment, Blood Plasmas, Studies, biological marker., plasmaFresh, data, Frozen Plasma, multi-cellular organism, AU023367, Fresh Frozen Plasma, mol, body, animalia, Blood, Arts, Proteins, number, Gene, whole body, Spectrum Analyses, Plasmas, Xt, presence, Spectrum Analysis, Cell, microparticle, add, Spectroscopy, Frozen Plasmas, polypeptide, organism, count in organism, Tier, GLI3-190, count, Protein, Proteomes., Gene Products, Mass, Analysis, animal, Bph, Mass Spectrum Analyses, Mass Spectroscopy, Mass Spectrum Analysis, Plasma, ADHD, Mass Spectrum, Fresh Frozen Plasmas, Fresh Frozen, Blood Plasma, portion of blood plasma, Industrial, whole organism, Industrial Arts, Analyses, cell, GLI3FL, AI854843, Spectrometry, portion of plasma, metazoa, proteins, Pdn, Protein Gene Products, Gene Proteins, blood plasm, Blood Plasmas, Koerper, Attention Deficit Hyperactivity Disorder, quantitative, Proteomes, plasma, presence or absence in organismPlasma, Fresh, Fresh Frozen Plasmas, Fresh Frozen, Blood Plasma, portion of blood plasma, Frozen Plasma, Procedures, Fresh Frozen Plasma, Blood, portion of plasma, Methodological, Procedure, Methodological Study, Plasmas, plan specification, Study, Frozen Plasmas, method, blood plasm, Methodological Studies, Method, method used in an experiment, Blood Plasmas, Studies, biological marker., plasmaAPS, Viral Marker, Biological Markers, Surrogate Endpoints, AU023367, Laboratory, Blood, Aminosaeure, Biochemical, Endpoint, NEOPL PROSTATIC, Serum, Experimental Medicine., composed of, microparticle, Laboratory Markers, Biological, Line, Antigen, KLK2A1, Analysis, Carcinoma of the Prostate, Kallikrein-3, Isotopically-Coded Affinity Tagging, MIX, Mass Spectrum Analysis, ADHD, treatment, Fresh Frozen Plasmas, Fresh Frozen, AAP-S, human disease, me75, amino acids, Adenocarcinoma of the Prostate, Identification, Analyses, Klk3, PTPSTEP, cell line cell, composition, proteins, elevated, NLS2, D17Mit170, T1, cell line, R74825, goku, Prostatic Neoplasm, Immune, Markers, Cancer of the Prostate, Viral Markers, disease management, Medicine, Homo sapiens disease, Tagging, "malignant tumor of the prostate" EXACT [NCI2004_11_17:C7378], plasma, Stable Isotope Labeling, Prostates, Frozen Plasma, Viral, THPH5, Surrogate Endpoint, THPH6, Aminokarbonsaeure, Arts, Biochemical Markers, Tl3, Entire prostate, Plasmas, Biologic Marker, Tl2, Spectrum Analysis, Psa, PSA, add, Spectroscopy, Experimental, count, Marker, Diseases, 3.1.3.48, ZNF912, Lines, MILD1, portion of blood plasma, Industrial, Industrial Arts, End Points, Step, GLI3FL, AI854843, content, Spectrometry, Identifications (Psychology), Striatum-enriched protein-tyrosine phosphatase, Immunologic, Laboratory Marker, Pdn, Carcinoma of Prostate, blood plasm, Patient, Biochemical Marker, STEP, Acids, Seminin, prostate, Proteomes, Prostate, prostata, "malignant tumor of prostate (disorder)" EXACT [SNOMEDCT_2005_07_31:363448003], PSATD, Fresh, Fresh Frozen Plasma, PROSTATIC NEOPL, Gamma-seminoprotein, Prostate Neoplasms, Clinical Markers, MP100, Clinical Marker, Adenocarcinoma of prostate (disorder), Neoplasms, number, Aminocarbonsaeure, "malignant tumor of prostate (disorder)" EXACT [SNOMEDCT_2005_07_31:399068003], Gene, Spectrum Analyses, Isotope-Coded Affinity, Xt, presence, NEOPL PROSTATE, Kal3, Biomedical, Surrogate End Points, Surrogate Markers, Investigative, Medical Research, Gene Products, Mass, Prostatic Cancers, EPIP, Low, Isotopically-Coded Affinity, Cancer of Prostate, Medical, Mass Spectroscopy, Prostate Cancers, PROS, Blood Plasma, Clinical, Research, Biological Marker, P-30 antigen, Prostatic Neoplasms, PSAT, Cytosol alanyl aminopeptidase, SGPA, D8Ertd814e, Immunologic Markers, Neural-specific protein-tyrosine phosphatase, Stable, Clients, Blood Plasmas, Isotope-Coded Affinity Tagging, Investigational Medicine, Prostatic, biological marker, adenocarcinoma of prostate, Immunologic Marker, high elevation, Biologic, Cancer, cou, Serum Markers, Proteins, Cell Lines, Kal-3, End Point, cell_line, 3.4.11.14, compositionality, Labeling, Client, Cell, Immune Marker, PS24, PS23, Frozen Plasmas, polypeptide, Isotope, PS25, Investigative Medicine, count in organism, Lr, PS22, PS21, GLI3-190, Surrogate End Point, Stable Isotope, male prostate, Protein, Prostatic Cancer, proteomic analysis, Neoplasm, Psat, hK3, MIXL, Bph, Isotope Coded Affinity Tagging, Mass Spectrum Analyses, Investigational, Biologic Markers, Plasma, Mass Spectrum, Semenogelase, Serum Marker, 3.4.21.77, distinct, Surrogate, Endpoints, portion of plasma, patient, Cancers, Isotope Labeling, Amino, Affinity Tagging, Isotopically-Coded, Surrogate Marker, Prostate Neoplasm, Protein Gene Products, Gene Proteins, "prostatic cancer" EXACT [CSP2005:2016-2641], structure, Bra, Isotope-Coded, PC, Attention Deficit Hyperactivity Disorder, quantitative, PROSTATE NEOPL, Prostate Cancer, Immune Markers, presence or absence in organism3605http://gpmdb.thegpm.org/~/dblist_gpmnum/gpmnum=GPM32320007536dbgap_ncbi~0patentfamilies~0rfam~0merops~0complex-portal~0uniprot~0wormbaseparasite~0embl-covid19~0reactome~0emdb~0wgs_masters~0ebiweb_resources~0opentargets_genetics~0biomodels_all~0ipd-mhc~0ebiweb_teams~0taxonomy~0genome_assembly~0sc-experiments~0ebiweb_people~0enzymeportal_enzymes~0ipd-nhkir~0cellosaurus~0pdbe~0chebi~0patentproteins~0interpro7~0uniref~0chembl~0pdbekb~0gpcrdb~0hgnc~0sc-genes~0intact~0rhea~0ebiweb_training~0alphafold~0imgt-hla~0patentnucleotides~0ensemblroot~0eva_studies~0non-coding~0europepmc~0pubmed~1identifiers_registry~0pdbechem~0hpa-covid19~0eva-variants-covid19~0biosamples~0gwas_catalog~0biotools~0tls_masters~0mesh~0coding~0sra~0opentargets~0efo~0embl-pathogen~0project~0pride~1human_diseases~0geo_datasets~0embl~0treefam~0uniparc~0ols~0dgva~0intenz~0go~0tsa_masters~0biosamples-covid19~0ebiweb_corporate~0omim~0lrg~0earlycause-molecular-sequences~0ipd-kir~0empiar~0rnacentral~0orcid_data_claims~0gpmdb~2lineage-covid19~0metagenomics~0pfam~0pride archive~1varsite~00Resource Reanalysis0.00.00.0111042566317088220.01.0falsePROMIS-Quan: a novel proteomic method for plasma biomarker quantificationData from ProteomeXchange, PXD ID: PXD001194. File: Animal_20141209_MH_MPs_PC_9.mzml. Published as part of Mol Cell Proteomics. 2015 Jan 26 . From the Abstract: {{i}} To overcome this challenge we analyzed the plasma microparticle proteome, and reached an unprecedented depth of over 3,000 plasma proteins in single runs. To add a quantitative dimension, we developed PROMIS-Quan PROteomics of MIcroparticles with Super-SILAC Quantification, a novel mass spectrometry-based technology for plasma microparticle proteome quantification ... {{/i}}2015-02-05GPM3232000753625624350PXD001194PXD001194